Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Receivables (2022 - 2025)

Historic Receivables for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $115.1 million.

  • Arcutis Biotherapeutics' Receivables rose 9148.02% to $115.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.1 million, marking a year-over-year increase of 9148.02%. This contributed to the annual value of $73.1 million for FY2024, which is 18312.47% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Receivables is $115.1 million, which was up 9148.02% from $106.7 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Receivables peaked at $115.1 million during Q3 2025, and registered a low of $2.4 million during Q3 2022.
  • Over the past 4 years, Arcutis Biotherapeutics' median Receivables value was $37.2 million (recorded in 2024), while the average stood at $46.7 million.
  • In the last 5 years, Arcutis Biotherapeutics' Receivables skyrocketed by 69872.48% in 2023 and then surged by 9148.02% in 2025.
  • Arcutis Biotherapeutics' Receivables (Quarter) stood at $8.5 million in 2022, then skyrocketed by 205.12% to $25.8 million in 2023, then surged by 183.12% to $73.1 million in 2024, then surged by 57.55% to $115.1 million in 2025.
  • Its Receivables stands at $115.1 million for Q3 2025, versus $106.7 million for Q2 2025 and $85.4 million for Q1 2025.